Asoprisnil

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Asoprisnil
Asoprisnil.svg
Systematic (IUPAC) name
rel-4-[(8R,11S,13R,14R,17R)-17-Methoxy-17-
Identifiers
CAS Number 199396-76-4 N
ATC code none
PubChem CID: 9577221
IUPHAR/BPS 2883
ChemSpider 7851660 YesY
UNII 72W09924WP YesY
KEGG D02996 YesY
ChEMBL CHEMBL267431 YesY
Chemical data
Formula C28H35NO4
Molecular mass 449.582 g/mol
  • O=C5\C=C4/C(=C3/[C@@H](c1ccc(\C=N\O)cc1)C[C@]2([C@@H](CC[C@@]2(OC)COC)[C@@H]3CC4)C)CC5
  • InChI=1S/C28H35NO4/c1-27-15-24(19-6-4-18(5-7-19)16-29-31)26-22-11-9-21(30)14-20(22)8-10-23(26)25(27)12-13-28(27,33-3)17-32-2/h4-7,14,16,23-25,31H,8-13,15,17H2,1-3H3/b29-16+/t23-,24+,25-,27-,28+/m0/s1 YesY
  • Key:GJMNAFGEUJBOCE-MEQIQULJSA-N YesY
 NYesY (what is this?)  (verify)

Asoprisnil (J867) is an investigational selective progesterone-receptor modulator developed by Schering and TAP Pharmaceutical Products, tested for treatment of progesterone-sensitive myomata.[1]

In 2005, phase-III trials were discontinued due to endometrial changes in patients. Whether asoprisnil will be marketed is uncertain.[2]

References

  1. Lua error in package.lua at line 80: module 'strict' not found.
  2. Schering Interim Report Q1-3 2005


<templatestyles src="Asbox/styles.css"></templatestyles>